 Neuronetics Inc NASDAQ: STIM reported Q4 FY21 sales of 15.02 million, down 4 YY, exceeding previously issued guidance of 13.0 million - 14.0 million and the consensus of 14.43 million. U.S. revenue decreased by 3 during the quarter, and international revenue decreased by 13 YY. 